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Abstract
Background: Repeat infection with Chlamydia trachomatis is common and increases the risk of sequelae in women
and HIV seroconversion in men who have sex with men (MSM). Despite guidelines recommending chlamydia
retesting three months after treatment, retesting rates are low. We are conducting the first randomised controlled
trial to assess the effectiveness of home collection combined with short message service (SMS) reminders on
chlamydia retesting and reinfection rates in three risk groups.
Methods/Design: The REACT (retest after Chlamydia trachomatis) trial involves 600 patients diagnosed with chlamydia:
200 MSM, 200 women and 200 heterosexual men recruited from two Australian sexual health clinics where SMS
reminders for retesting are routine practice. Participants will be randomised to the home group (3-month SMS
reminder and home-collection) or the clinic group (3-month SMS reminder to return to the clinic). Participants in the
home group will be given the choice of attending the clinic if they prefer. The mailed home-collection kit includes a
self-collected vaginal swab (women), UriSWAB (Copan) for urine collection (heterosexual men), and UriSWAB plus rectal
swab (MSM). The primary outcome is the retest rate at 1-4 months after a chlamydia diagnosis, and the secondary
outcomes are: the repeat positive test rate; the reinfection rate; the acceptability of home testing with SMS reminders;
and the cost effectiveness of home testing. Sexual behaviour data collected via an online survey at 4-5 months, and
genotyping of repeat infections, will be used to discriminate reinfections from treatment failures. The trial will be
conducted over two years. An intention to treat analysis will be conducted.
Discussion: This study will provide evidence about the effectiveness of home-collection combined with SMS reminders
on chlamydia retesting, repeat infection and reinfection rates in three risk groups. The trial will determine client
acceptability and cost effectiveness of this strategy.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12611000968976.
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Background
Chlamydia trachomatis is the most frequently reported
sexually transmitted infection in most developed coun-
tries and notification rates are increasing steadily each
year [1-3]. In many countries, the greatest burden of in-
fection is among young heterosexual men and women
aged 15-24 years, with population-based prevalence esti-
mates ranging from 3 to 6% [4-7]. High prevalence rates
have also been reported in men who have sex with men
(MSM), ranging from 5 to 9% for rectal infections and 3
to 6% for urethral infections [8-11].
Repeat chlamydial infections
Repeat chlamydial infections following treatment are also
common. In a prospective cohort of 16-24 year old women
attending general practices in the United Kingdom, a re-
peat infection rate of 29.9% per year following treatment
was reported (95% confidence interval [CI]: 19.7-45.4%)
[12]. An Australian cohort of 1116 women aged 16-25
years reported a repeat infection rate of 18% at 3 months
(95% CI: 8-34%) and 22.3% by 12 months (95% CI: 13.2,
37.6) following treatment [13]. In a review of eight studies,
it was reported that 10.9% of heterosexual of men with ac-
tive follow-up had a repeat infection at 4 months [14].
Higher rates of repeat infection after treatment have been
reported in MSM [15]. Repeat chlamydial infections in-
crease the risk of chlamydia-related sequelae such as pelvic
inflammatory disease and infertility, when compared to
initial infection [16], and in MSM, repeat rectal chlamydia
or gonorrhoea infections have been associated with an in-
creased risk of HIV seroconversion [17].
Repeat positive chlamydia tests may result from re-
infection from the same partner, an infection from a
new partner, inadequate treatment or treatment failure
[18]. Batteiger et al. found that of the repeat positive
tests among young women participating in a longitudinal
cohort, 84.2% were definite, probable, or possible rein-
fections (different genotypes +/- unprotected sex); 13.7%
were probable or possible treatment failures; and 2.2%
persisted without documented treatment [18]. This study
and others [19,20], have demonstrated that treatment
failure with azithromycin may be a contributing factor
in repeat positive chlamydia tests, and this has been the
subject of recent debate [21,22].
Chlamydia retesting
Retesting at 3 months is important to prevent onward
transmission and sequelae associated with repeat infec-
tions. Given that the majority of repeat infections are
the result of existing partners not being treated, repeat
positivity is also an important indicator of the effective-
ness of partner notification.
Although clinical guidelines in a number of coun-
tries recommend retesting after treatment for chlamydia
[23-27], retesting rates are low, especially amongst men.
In a recent analysis of 2008-2010 United States (US)
laboratory data, chlamydia retesting rates within a year
among men and non-pregnant women, were 22% and
38% respectively [28]. In a 5-year period between 2004
and 2008, the proportion of Australian sexual health ser-
vice patients with chlamydia infection who were retested
in 30-120 days was 8.6% in MSM, 11.9% in heterosexual
males and 17.8% in heterosexual females [29]. In England,
retesting rates within a year among 15 to 24 year olds in
2010 ranged from 18.4% in the National Chlamydia
Screening Program dataset to 26.1% in the genitourinary
medicine clinic activity dataset [30].
The true clinical impact of increased rescreening has
not yet been established. Of the interventions aiming to
increase retesting conducted to date, few measured re-
peat positive tests and none discriminated between
reinfections and treatment failures [31-37]. Among the
interventions which did report repeat positive test rates,
despite higher retesting rates, the rate of repeat infection
in all but one study, was lower in the intervention arm
compared with the control arm. However only one study
showed this difference was statistically different.
Based on the study by Batteiger et al. [18], the majority
of repeat positive tests would be expected to be reinfec-
tions, which suggests that rescreening strategies may be
reaching more asymptomatic patients and those at lower
risk of reinfection. For example, in the postcard reminder
study by Paneth-Pollack et al. [32], 50% of retesters in the
intervention arm were asymptomatic compared to 23% in
the control group. People with symptoms may be more
likely to initiate retesting, and this may help to account for
the lower rates of repeat infection found, despite higher
retesting rates. This highlights the importance of measur-
ing both retesting and repeat positive test rates in studies
which aim to increase retesting.
The high sensitivity of nucleic acid amplification tests
(NAAT) has enabled the use of self-collected specimens,
such as urine and vaginal swabs, for the diagnosis and
screening of chlamydia and gonococcal infections [38].
Self-collected urine, vaginal and rectal specimens have been
widely used in a variety of clinical and non-clinical settings
to increase access to chlamydia screening and rescreening
[37,39-42] and have been found to be acceptable in men
and women [43-46]. A previous study in Australia has con-
firmed the robustness of swabs when transported for up to
a week through routine postal systems [47].
Interventions to increase chlamydia retesting
Mailed home collection kits have been demonstrated in a
meta-analysis of controlled studies by Guy and colleagues,
to increase retesting rates by an average of 30% (pooled ef-
fect estimate = 1.30; 95% CI: 1.10-1.50) [48]. The same
meta-analysis showed reminder strategies including phone
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calls (+/- letters) and postcard reminders also resulted in a
modest increase in rescreening.
A reminder strategy that was not used in the studies
reviewed by Guy et al. was the use of short message ser-
vices (SMS) reminders. SMS and telephone reminders have
been found to be effective for a variety of health related
purposes such as reducing missed appointments [49] and
increasing vaccination uptake [50], with SMS reminders
shown to be more cost-effective [49,51]. SMS reminders
have the advantage of automation, convenience, confidenti-
ality and immediacy [52] and have been found to be accept-
able in the sexual health context [53,54]. Subsequent to the
review by Guy et al. [48], three Australian before-after stud-
ies have demonstrated that SMS reminders increase STI
retesting rates in sexual health clinic patients [35,52,55].
Cost effectiveness
There is limited evidence regarding the cost effectiveness
of home-based versus clinic based rescreening for sexu-
ally transmitted infections. A study by Xu et al. found
home-collection to be less costly than clinic-based
rescreening at $54 per self-collected test versus $118 per
clinic-based test [33].
We describe here a randomised controlled trial that aims
to assess the effectiveness of home-collection combined
with SMS reminders on chlamydia retesting rates in MSM,
women and heterosexual men. The trial will also determine
client acceptability and cost effectiveness of the approach.
Methods/Design
Study design/setting
This is a non-blinded, randomised controlled trial (RCT)
where individuals are randomised in a 1:1 ratio to an
SMS reminder and home-based, self-collected samples
(home group) or an SMS reminder and clinic testing (clinic
group). The trial is being conducted in two Australian
sexual health clinics (Melbourne and Sydney Sexual Health
Centres). The study is diagrammatically represented in
Figure 1.
Research objectives
The primary objective of the trial is to compare the retest
rate 1-4 months after treatment for chlamydia among par-
ticipants in the home group (3-month SMS reminder and
home-collection) compared with the clinic group (3-
month SMS reminder to return to the clinic). The second-
ary objectives are to: compare the chlamydia repeat
positive test rate in participants in the home group com-
pared with the clinic group; assess the reinfection rate
among participants who retested; determine the accept-
ability of home-based testing with SMS reminders; and
compare health provider costs of home-based specimen
collection with routine (clinic based) retesting.
Duration of trial
The study will require 24 months to complete: 6 months
for recruitment and 18 months to complete follow-up,
data collection and analysis.
Blinding
Given the nature of the intervention, it is not possible to
blind the patient to their trial group. However, the statis-

















Researcher obtains verbal consent from patient 
Researcher sends SMS reminder to complete the survey online
Researcher contacts the patient’s usual GP or other clinics nominated by the 
participant
Clinic sends SMS reminder to retest
Researcher sends 2nd SMS reminder to complete the survey online
Figure 1 Schematic of REACT study design.
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Ethical considerations
The REACT study protocol has been approved by the
Alfred Health Human Research Ethics Committee (HREC),
South Eastern Sydney and Illawarra Area Health Service
HREC and the University of New South Wales HREC.
Trial inclusion and exclusion criteria
Patients will be included if they: are aged 16 years or
above; have a mobile phone; are heterosexual men (re-
ported sexual contact only with female partner/s in the
last 12 months)/MSM (reported sexual contact with
male partner/s in the last 12 months)/or women; have a
diagnosis of chlamydia infection (diagnosed by NAAT);
and reside in a jurisdiction serviced by the sexual health
clinic and plan to stay in that jurisdiction for the next
six months. Patients will be excluded if they: are unwill-
ing or unable to comply with all the requirements of the
protocol; cannot speak English; are HIV positive or a
current sex worker.
Recruitment
A total of 600 participants (200 MSM, 200 women and
200 heterosexual men) diagnosed with chlamydia are re-
quired. The trial will be advertised by postcards left in
the waiting room or provided to patients at the time of
chlamydia testing or treatment. All positive chlamydia
results will be reviewed by study nurses based at each of
the clinics. Among potentially eligible patients, the nurse
will contact the patient by telephone and let them know
of their chlamydia diagnosis and for those not already
treated, recommend they come to the clinic for treat-
ment. During the call the nurse will give a brief overview
of the study and asked the patient for permission to pass
on their contact details to a member of the research
team. If the patient agrees, a member of the research
team will then contact the patient to explain the trial re-
quirements and undertake a verbal consent process.
Randomisation
Eligible patients will be randomised to the intervention
or control strategies using a minimisation approach.
This will maximise the balance across the risk groups
(MSM, women and heterosexual men). Computer gener-
ated randomisation codes, stratified for risk group will
be produced by a statistician and sealed in opaque enve-
lopes. Once consent has been given, the research team
member will select the next randomisation envelope ac-
cording to the risk group of the patient and inform the
patient which group they have been assigned to – the
home or clinic group.
Intervention (home testing) arm
The home-collection kit will contain the collection device,
illustrated collection instructions, laboratory request form
and pre-paid envelope. The collection devices will vary
according to the patient’s risk group as follows: for het-
erosexual men the collection device will consist of a
sponge-based urine collection device (UriSWAB®, Copan
Diagnostics, CA, USA); for women the collection device
will consist of a swab for lower vaginal self-collection
and for MSM two collection devices will be provided: (i)
a swab for rectal self-collection; and (ii) a UriSWAB for
first-pass urine collection.
The swabs and request form will be pre-labelled with
identifying information. Three months after chlamydia
diagnosis, the clinic will send an SMS reminder to en-
courage the patient to either: (i) return to the clinic for
retesting; or (ii) collect a sample/s using the collection
kit and mail it to the lab with the request slip. A
purpose-built database will be used to generate a list of
patients due to be mailed home-collection kits. The col-
lection kit will be mailed to the patient in an unmarked
envelope by the research team. Patients will be instructed
in a covering letter to collect their specimen/s and pack-
age them according to the instructions provided and mail
them to the laboratory in the pre-paid envelope.
Control (standard care) arm
Three months after chlamydia diagnosis patients will be
sent an SMS reminder by the clinic to encourage them
to return to the clinic for retesting. This is routine prac-
tice at the two participating clinics.
Specimen processing, testing and results
Chlamydia testing
The baseline chlamydia positive specimens (600) and
clinic group retesting specimens will be tested by the
clinic’s usual pathology provider. Specimen collection
and processing will be in accordance with the pathology
provider’s usual protocol, and pathology providers will
be requested to store chlamydia positive baseline and re-
test specimens until the end of the trial. Results will be
given to patients according to the clinic’s protocol for
managing test results. Treatment for chlamydia positive
cases is 1g single dose azithromycin according to the
routine practice [25].
All home group retesting specimens will be processed
by a specialist laboratory. The laboratory will also be
asked to store the specimens until the end of the trial.
Results will be reported back to, and managed by the re-
ferring clinics, in the usual manner.
Serovar detection
Confirmation of each chlamydia serovar, and detection
of genotypic variants will be determined by qPCR assay
and DNA sequencing [56]. qPCR will be performed in a
primary chlamydia group-specific multiplex PCR which
utilises two primers and four probes, specific to all
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chlamydia types, including the B group (B, E, D, L1, and
L2), C group (A, C, H, I, J, K, and L3) or intermediate
group (F and G) serovars. The primary group-specific
PCR will be used to determine which set of secondary
serovar-specific PCRs to perform, as described previ-
ously [56]. When the same serovar is detected at diagno-
sis and follow-up, further discriminatory confirmation of
relatedness using multilocus sequence typing (MLST)
will be conducted [57].
Outcomes
The primary outcome is the proportion of patients who
retest between 1-4 months after a chlamydia diagnosis.
The secondary outcomes are:
1. The repeat positive test rate.
2. Reinfection rate.
3. Acceptability of home testing with SMS reminders.
4. Cost effectiveness of home testing.
Data collection methods and variables
Clinical and sexual behaviour data
Among all patients who test positive at the study site in
the recruitment period a range of variables (condom
use, number of partners, previous chlamydia diagnoses,
anal and uro-genital symptoms, treatment and chla-
mydia results) will be extracted from the patient man-
agement system for all episodes of care during the trial
period.
Acceptability data
Participants in both study arms will be asked to com-
plete a quantitative survey online. An SMS reminder will
be sent to participants at 4.5 and 5 months (after ascer-
tainment of the primary outcome). The SMS will contain
the study website and the participant’s code which is
linked to their patient details captured at consent. The
survey will investigate participants’ living situation (with
parents or not), chlamydia treatment for themselves and
partners, sexual behaviour, retesting at the same clinic
or elsewhere, reasons for not retesting, acceptability of
SMS reminders, and for participants in the home group,
the acceptability of home testing, ease of collection and
retesting preferences (home or clinic retesting). On com-
pletion of the survey participants will be sent a $40
AUD voucher, irrespective of retesting. If the participant
notes on the online survey that they had a chlamydia
test at a clinic other than the sexual health clinic since
their positive test, the participant will be mailed a con-
sent form to obtain their permission to contact this
clinic to obtain the results of this test. The consent form
will then be mailed to the doctor at the clinic.
Cost analysis data
The cost of an organised chlamydia retesting program
will be assessed from the perspective of the health care
provider only. Cost data will relate to patients seen in
the 12 months prior to the commencement of the study.
De-identified data will be extracted from the patient
management system for each patient interaction includ-
ing: triage time, consultation time, staff type, risk group
of client, type of clinic (regular or fast track clinical ser-
vice known as the express clinic) and number of SMS
reminders sent. Where these data are not available
through the patient management system, (for example
phone times and administration time), log sheets will be
developed for the relevant staff members to document
the time taken for each interaction.
Analysis
Chlamydia retesting and repeat positive test rates
The final analysis of primary and secondary outcomes
will be performed at the conclusion of the trial. Patient
baseline characteristics will be compared by randomised
group as appropriate but no formal statistical tests will
be undertaken. Analyses will be conducted using STATA
statistical analysis software. An intention-to-treat ap-
proach will be taken.
In the initial analysis, the percentage of individuals
who returned will be cross tabulated by randomised
group. The analysis will determine the effect of the inter-
vention on primary and secondary outcomes overall and
between risk groups (MSM, women and heterosexual
men). The primary analysis will be retesting rates be-
tween 1-4 months after a chlamydia diagnosis. Per
protocol analyses will include: i) among the home-
testing arm: the percentage who retested at home com-
pared with the clinic, and the median time to retest
among those who tested at the clinic versus home; ii) in
each arm: the median time to retest (overall and in those
who retested positive); and iii) factors associated with re-
peat positivity among those who retested at 1-4 months.
Reinfection rate
Consistent with the algorithm described by Batteiger
[18] repeat positive cases will be discriminated using
sexual behaviour data (from the questionnaires and data
extracted from the patient management system) and
chlamydia genotyping. To differentiate between chla-
mydia reinfection, treatment failure or persistent infec-
tion, we will use a modified version of the chlamydia
repeat infection algorithm developed by Batteiger et al.
[18] and adapted by Walker et al. [13] (Figure 2). If a
participant has two infections with different genotypes,
then the second infection will be considered a reinfec-
tion. If participants received appropriate treatment but
had unprotected sex with their current or new partners,
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the second infection will also be considered a reinfec-
tion. Treatment failure will be defined as a positive chla-
mydia result following appropriate treatment if the
participant reported either no sex between the two epi-
sodes or always using condoms with sex. An infection
will be defined as persistent if the participant has two
consecutive positive chlamydia test results and was not
treated between episodes [18,13].
Acceptability
The acceptability of home-testing in the home group
participants will be compared in the three different risk
groups using a Chi-2 test, with breakdowns according to
age group, sex, symptoms and sexual behaviour. Factors
associated with acceptability will be assessed using
multivariate logistic regression. The primary outcome of
the analysis will be preference for home-testing.
Cost analysis
In order to estimate the costs of each component of
retesting, a flowchart will be constructed to describe the
pathway of patients from their initial chlamydia test, no-
tification of results and treatment, to retest, either at the
clinic or via home-based collection, notification of re-
sults and treatment. Labour costs will be estimated
based on time, staff type and average salary. All equip-
ment for each clinical interaction will be listed and
priced according to clinic inventories. The costs of diag-
nostic testing will be based on the Medicare Benefits
Schedule (a listing of the Medicare services subsidised
by the Australian government). The cost of clinic and
home-based retesting will be compared. The cost of test-
ing at the regular clinic versus the express clinic and be-
tween risk groups will also be compared. Using the cost
data and primary outcome data of retesting and repeat
positive test rates, a cost-effectiveness analysis will be
undertaken.
Data storage
A central database containing de-identified quantitative
trial data will be held at the Kirby Institute. All elec-
tronic files will be password protected and only the trial
research staff and statistician will have access. Partici-
pants’ contact details will be securely stored separately
to the quantitative trial data.
Sample size calculation
The sample size is based on a chlamydia retesting rate of
40% in the clinic group (receiving the SMS) based on
findings from previous studies. In the analysis we are in-
terested in assessing the primary outcome in the three
risk groups (200 MSM, 200 women and 200 heterosex-
ual men) and overall. A sample size of 194 in each risk
group will achieve at least 80% statistical power to detect
an overall 20% difference (60% compared to 40%) in
retesting between home and clinic groups. The 194 will
be rounded to 200, and summed up to give an overall
sample size of 600. A total sample size of 600 will
achieve at least 80% statistical power to detect an overall
12% difference (52% compared to 40%) between home
and clinic group for all three risk groups combined. As-
suming the retesting rates above are achieved, and the
repeat positivity in the clinic group is 10%, we have 80%
power to detect an increase of 13% (10% compared to
23%) in repeat positivity.
Registration
This trial is registered with the Australian and New Zealand
Clinical Trials Registry: ACTRN12611000968976.
Discussion
Chlamydia retesting at 3 months after infection is an im-
portant strategy to detect reinfections and to monitor
the effectiveness of partner notification, but retesting
rates are low. There is some evidence from other studies
that home-based specimen collection results in a modest
increase in retesting for repeat chlamydial infection as
do SMS reminders, but no studies have combined these
two strategies.
One of the major problems in interpreting the findings
from studies to date is suboptimal study designs. Many
of the studies included in the review by Guy et al. [48]
were evaluated using a before-after design and it is
Same serovar for both 
episodes?
Two episodes of chlamydia 
infection
Treatment between episodes?
Condoms used with all coitus/  
No sex?
Coitus with same partner? 















Figure 2 Algorithm to differentiate between chlamydia
reinfection, treatment failure and persistent infection (adapted
from Batteiger et al. [18] and Walker et al. [13]). N/A = Genotype
result not available.
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possible that the intervention group patients may have
had characteristics which facilitated rescreening irre-
spective of receiving the intervention. Few studies aimed
to control for these differences. Some may also have
underestimated retesting as a proportion of patients may
have undergone screening at other health services. Sev-
eral studies also had small sample sizes, precluding any
analysis of the differential impact according to risk be-
haviour, symptoms or demographics. Another limitation
of the intervention research in this area is that most
studies have defined a repeat positive test as a reinfec-
tion. However repeat positive tests results may represent
reinfections, persistence without treatment, or treatment
failure, with varying implications for each. In addition
many of the previous retesting studies included women
only [31,33,36].
Most of the previous interventions which have aimed
to increase retesting have focused on offering people one
strategy or another. However people may choose differ-
ent retesting strategies depending on their personal cir-
cumstances. For example, in a US study by Sparks et al.
[58], heterosexuals aged 14 years or older were given a
choice of either mailing a specimen for testing or return-
ing to the clinic for retesting, and 30% of participants in
the intervention arm chose the mailed retesting option
compared with 70% who opted to attend the clinic for
rescreening. Another US study of home screening by
Cook et al. [31] reported that although most young
women (179) received their home-collection kit in the
mail, 18 (9%) opted to pick it up from the clinic, and a
study in Australia found that young people were less
likely to return home-collection kits if they lived with
their parents [59]. These findings highlight that to maxi-
mise the effectiveness of an intervention, it is important
to provide different options to suit the diverse needs and
preferences of different risk groups and individuals.
This world first trial will provide evidence about the
effectiveness of home collection and SMS reminders as a
combined strategy, to increase retesting and detect re-
peat positive tests following treatment for chlamydia in
three risk groups (MSM, women and heterosexual men),
as well as providing information about the acceptability
and cost effectiveness of this strategy. Given limited re-
sources, offering innovative and effective ways to im-
prove retesting rates in those at highest risk of
reproductive and other chlamydia-related morbidity and
HIV transmission, is an important strategy for chlamydia
control.
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